Drugs / Autologous BAFFR-targeting CAR T Cells
Autologous BAFFR-targeting CAR T Cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06191887 | Mar 2024 → Dec 2040 expected | Richter transformation, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma +2 | Mayo Clinic | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous BAFFR-targeting CAR T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06191887 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T-cells” NCT06191887 ↗ |
| Route | Intravenous | “Given IV” NCT06191887 ↗ |